7D2A Stock Chart & Stats
€0.90
-€0.09(-6.01%)
At close: 4:00 PM EST
€0.90
-€0.09(-6.01%)
Day’s Range― - ―
52-Week Range€0.67 - €1.52
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€80.16M
Enterprise Value€776.21M
Total Cash (Recent Filing)€80.68M
Total Debt (Recent Filing)€7.56M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Jul 17, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding99,336,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€18.84M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetExtremely low debt (debt-to-equity ~0.5% TTM) gives the company durable financial flexibility. This reduces insolvency risk, supports continued R&D/commercial investment while loss-making, and lengthens runway versus peers reliant on external financing.
High Gross Margins (~71%)Sustained gross margins near 71% indicate advantaged product economics and pricing power for the Sedaconda portfolio. High product margins provide the structural basis for future operating leverage once revenue growth returns or fixed costs are better absorbed.
Recurring Consumables-driven Revenue ModelA business model combining a proprietary pharmaceutical and per-use consumables creates recurring, per-patient revenue streams. This structural revenue mix supports predictable unit economics and the potential for steady attach-rate growth in hospitals over time.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow (TTM ~-47.8M) signals ongoing cash burn. Over months this increases reliance on existing liquidity or new funding, constrains reinvestment, and raises execution risk if profitability or external financing does not improve.
Structurally Loss-making (negative EBIT & Net Margin)Negative EBIT (~-16%) and net margin (~-29.6%) indicate the business has not achieved operating profitability. Continued losses erode equity returns, limit internal funding for commercialization, and require clear path-to-profit to sustain long-term value creation.
Stagnant To Declining Revenue TrendRevenue roughly flat to down (~-2% TTM) undermines the company's ability to scale fixed-cost investments and realize operating leverage. Without sustained top-line growth, executing on commercial expansion or recovering profitability will remain challenging.
Sedana Medical AB News
7D2A FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was €0.67 and its highest was €1.52 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is €80.16M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Jul 17, 2026 which is in 6 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Apr 23, 2026. The company reported -€0.004 earnings per share for the quarter, beating the consensus estimate of -€0.004 by <€0.001.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is >-0.01.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -€0.004 in its last earnings report, beating expectations of -€0.004. Following the earnings report the stock price went down -5.234%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in DE:7D2A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical tools designed for delivering volatile anesthetics, alongside the Sedaconda Syringe (a 50/60ml syringe) and a Sedaconda ACD starter kit. The company also provides FlurAbsorb and FlurAbsorb-S, active carbon filtration systems engineered to collect residual anesthetic gases discharged by ventilators. Complementing these are the FlurAbsorb accessory kit, which facilitates connecting ventilator exhausts and gas monitors to the filters, and the FlurAbsorb mount, used to secure the filter during anesthetic gas removal. Further offerings encompass the AMG-06 Gas Monitor, which enables ongoing, non-invasive sidestream measurement of carbon dioxide and anesthetic levels in inhaled and exhaled breaths. Additionally, they supply the Sedaconda Filling Adapter, a disposable tool for securely and simply transferring isoflurane from its container to a Sedaconda Syringe, as well as an array of supplemental items like DRYLINE II Water Traps, the WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Lines. Established in 1999, Sedana Medical AB (publ) maintains its corporate headquarters in Danderyd, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---